Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020;95:e2075–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi D, Xie S, Li A, Wang Q, Guo H, Han Y, et al. APOE-ε4 modulates the association among plasma Aβ42/Aβ40, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults. Transl Psychiatry. 2022;12:128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Y, Shi D, Lan G, Chen L, Jiang Y, Zhou L, et al. Association of β-Amyloid, Microglial activation, cortical thickness, and metabolism in older adults without dementia. Neurology. 2024;102:e209205.

Article  CAS  PubMed  Google Scholar 

Guo T, Landau SM, Jagust WJ. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94:e1512–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I. Rate of β-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimer’s Dement. 2018;14:1387–96.

Article  Google Scholar 

Guo T, Korman D, La Joie R, Shaw LM, Trojanowski JQ, Jagust WJ, et al. Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease. Alzheimers Res Ther. 2020;12:97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Y, Du J, Li A, Zhu Y, Xu L, Sun K, et al. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease. Alzheimers Res Ther. 2023;15:30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang C, Wang Q, Xie S, Chen Z, Fu L, Peng Q et al. β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns. Brain Commun. 2022;4.

Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer’s Disease Pathophysiology. Biol Psychiatry. 2021;89:786–94.

Article  CAS  PubMed  Google Scholar 

Lan G, Cai Y, Li A, Liu Z, Ma S, Guo T. Association of Presynaptic Loss with Alzheimer’s Disease and Cognitive decline. Ann Neurol. 2022;92:1001–15.

Article  CAS  PubMed  Google Scholar 

Lan G, Li A, Liu Z, Ma S, Guo T. Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline. Alzheimer’s Dement. 2023;19:2408–19.

Article  CAS  Google Scholar 

Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol. 2023;19:395–409.

Article  CAS  PubMed  Google Scholar 

Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I. Predicting Regional Pattern of Longitudinal β-Amyloid Accumulation by Baseline PET. J Nucl Med. 2017;58:639–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology. 2019;93:e1635–46.

Article  PubMed  Google Scholar 

Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019;92:e1567–79.

Article  PubMed  PubMed Central  Google Scholar 

Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of Elevated Amyloid and tau Positron Emission Tomography Signal with Near-Term Development of Alzheimer Disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79:975.

Article  PubMed  PubMed Central  Google Scholar 

Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack CR, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, Tau, and Neurodegeneration Biomarker profiles with Rates of memory decline among individuals without dementia. JAMA. 2019;321:2316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249–54.

Article  CAS  PubMed  Google Scholar 

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirtz C, Busto GU, Bennys K, Kindermans J, Navucet S, Tiers L, et al. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort. Alzheimers Res Ther. 2023;15:34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative disorders. JAMA. 2020;324:772.

Article  CAS  PubMed  Google Scholar 

Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422–33.

Article  CAS  PubMed  Google Scholar 

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379–86.

Article  CAS  PubMed  Google Scholar 

Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021;141:709–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, et al. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease. Nat Med. 2023;29:1775–81.